Handing down a 5-3 decision today, the U.S. Supreme Court ruled that the Federal Trade Commission can challenge closed-door deals that the big pharmaceutical companies make with smaller generic rivals to keep cheaper products off the market and out of drug stores.
(READ the news from Reuters)